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EMS Mutagenesis: E. coli strain NR698 was grown to mid-log phase (O.D. 600=0.5) and treated with 0.5% or 
1% EMS for 1 h at 37ºC.  Cells were washed with 5% sodium thiosulfate to inactivate the EMS. 104 to 106 cells
were transferred to fresh LB agar plates containing various concentrations of compound HO and incubated at 
37ºC until colonies formed.  The resistant colonies were further confirmed by numerous passages on selection 
plates and untreated NR698 cells were used as a control. 
Inhibition Assay: Efflux strains of S. aureus were grown on LB plates and inoculated in 2 mL of LB.  Different 
strains included K1758 (NorA-), K2361 (NorA++), K2908 (MepA-), WT (83254), and K2068 (MepA++).  The LB 
medium for the appropriate sample was treated with the corresponding antibiotic.  The treatment for K2361 
(NorA++) was Cm (2 µl/2 mL) and the Ery chemical treatment (8 µl/2 mL) was for the K1758 (NorA-) and K2908 
(MepA-).  The OD was measured and the mid-log samples were diluted to 0.05. The 5 different strains were then 
tested using different concentrations of antibiotic treatments.  They were left in the incubator for 14 hrs at 37°C
at 100 rpm. 
SecA translocation ATPase assay: Translocation ATPase assay was carried out at 40oC for 30 mins using 
Malachite Green colorimetric method.  Urea-treated SecA-depleted BA-13 membranes and preprotein pOmpA 
were used in the reaction. 
DARTS for purified protein binding: Ten- µg SecA protein was incubated at 37oC for 10 mins after the addition 
of the proper inhibitor.  The inhibitors include 0 mM, 2 mM, and 10 mM of HO, HA1, and NR698-17.  This was 
followed by digestion with 2 µl trypsin on ice for 10 mins.  Adding sample buffer and boiling for 20 mins stopped 
the digestion.  SDS-PAGE (12%) was used to investigate the trypsin digestion pattern. 
As HO increases, a new band is seen in the tryptic digest, indicating 
that the drug alters the SecA conformation. This could indicate that 
SecA is the target for HO.    
The compound HO was tested in samples with the  overexpression 
(++) and deletion (-) of MepA and NorA efflux pumps. 
HO is a potent inhibitor for SecA that seems to be unaffected by 
an efflux pump.  This particular compound, when bound to SecA 
alters the trypsin digest which indicates that HO changes the 
confirmation of SecA. 
This work was supported by  NIH Grant GM34676    
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http://journals.cambridgemedia.com.au/microbiology_australia/Past_Issues/Read_Article?id=202&i=28 
The compound HO was tested in samples with the  
overexpression (++) and deletion (-) of MepA and NorA efflux 
pumps as shown by the IC50 values. 
 Due to the misuse of conventional antibiotics and  
natural selection of the infectious bacterial population, drug 
resistance has emerged.  Thus, there is an increasing need for 
novel, more effective antibiotic compounds that are successful in 
treating bacterial infections currently resistant to available 
therapies. SecA is an indispensable ATPase of the protein 
translocation machinery present in all bacteria.  It is responsible 
for the secretion of many essential proteins, some toxins and 
virulence factors, and essential for bacterial survival. SecA has no 
counterpart in mammalian cells, thus providing an ideal target for 
developing antimicrobial agents. SCA-13 (HO) is a pyrimidine 
analog and was derived from 
Strains of S. aureus, suggesting that compound HO is not a 
substrate of NorA or MepA efflux pumps.  Resistant mutants of E. 
coli NR698 selected from HO will be characterized to gain a better 
understanding the mechanisms of resistance and subsequently find 
the drug target. 
One of the methods of resistance is for the compound/ treatment 
to be pumped out of the cell via an efflux pump.  We examined the 
effect of changes in the MepA and NorA efflux pumps on the HO 
compound.  MepA and NorA efflux pumps are illustrated above.  
NorA is a member of the SMR family of efflux pumps. 
http://biology.gsu.edu/5732.html 
IC50
virtual screening, exerts the ability 
to inhibit SecA translocation ATPase 
activity with an IC50 of 75 µM. 
Moreover, HO showed promising 
bacteriostatic activities against a 
vacomycin resistance strain of S. 
aureus Mu50 and B. anthracis 
Sterne. No significant difference in 
antimicrobial activity of HO was 
observed among efflux pump
 HO 
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